Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2014) 3 PP259 | DOI: 10.1530/boneabs.3.PP259

Osteoporosis: pathophysiology and epidemiology

High sclerostin levels in primary biliray cirrhosis: relationship with cholestasis and bone remodelling

Silvia Ruiz-Gaspà1, Laia Gifre2, Albert Parés1,3, Rosa Miquel4, Pilar Peris1,2, Ana Monegal2, Marta Dubreuil1, Ana Arias2 & Nuria Guañabens1,2

40 views


1Centro Network Biomedical Research in Hepatic and Digestive Diseases (CIBERehd), Hospital Clínic of Barcelona, Barcelona, Spain; 2Metabolic Bone Diseases Unit, Department of Rheumatology, Hospital Clínic of Barcelona, Barcelona, Spain; 3Liver Unit, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain; 4Department of Pathology, Hospital Clínic of Barcelona, Barcelona, Spain.


Background and aims: Low bone formation is the main pathogenic mechanism of osteoporosis in primary biliary cirrhosis (PBC). Sclerostin, an inhibitor of the Wnt pathway, is involved in the regulation of osteoblastogenesis and little is known about its role in the development of bone disease in PBC. Thus, we evaluated the circulating levels of sclerostin and its relationship to bone mass, the parameters of mineral metabolism and liver disease severity.

Methods: Serum sclerostin levels were measured in 83 women with PBC (mean age: 60±12 years) treated with ursodeoxycolic acid and 101 control women of the same age. In patients with PBC, we assessed the degree of cholestasis, lumbar and femoral BMD (DXA), as well as parameters of mineral metabolism (Ca/P, PTH, 25OHD, PINP, bone ALP, sCTX, NTX, and osteocalcin). In 20 PBC patients sclerostin levels were measured again after 5 years.

Results: 77% had low BMD (22% osteoporosis and 55% osteopenia). Patients with PBC showed higher sclerostin levels than controls (76.7±38.6 vs 32.5±14.7 pmol/l, P<0.001). Sclerostin levels were higher in patients with less severe cholestasis. A direct correlation between sclerostin and lumbar (r=0.354, P=0.002) and femoral BMD (r=0.336, P=0.003) and age (r=0.256, P=0.002) was observed. In the 65 patients not receiving bisphosphonates at the time of the evaluation, there was an inverse correlation of sclerostin with bone formation markers, PINP (P=0.05) and osteocalcin (P=0.037) and bone resorption, NTX (P=0.01) and sCTX (P=0.03). Sclerostin was significantly decreased in patients who were evaluated at 5 years (99.5±35.9 vs 60.1±30.9 pmol/l, P=0.001).

Conclusion: In primary biliary cirrhosis there is an increase in sclerostin, related to bone mass and liver disease severity. The inverse association with bone formation markers indicates that high sclerostin plays a role in the decreased bone formation in this liver disease.

Volume 3

European Calcified Tissue Society Congress 2014

Prague, Czech Republic
17 May 2014 - 20 May 2014

European Calcified Tissue Society 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts

No recent abstracts.